Altimmune, Inc.
ALTDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ALT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALT-801 | Phase 2 | Obesity/Overweight | - | - |
Pemvidutide | Phase 2 | Alcohol Use Disorder (AUD) | - | - |
NasoVAX | Phase 2 | Influenza | - | - |
Frequently asked questions
What is in Altimmune, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Altimmune, Inc.'s (ALT) pipeline across Phase 2. Its lead program is ALT-801 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Altimmune, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Altimmune, Inc. (ALT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALT biotech catalysts?→
Add ALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Altimmune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.